Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why These 5 Stocks Are Moving On High Volume Today

After opening in the green, the three major indexes are close to flat today, as volatility remains low. Among the stocks traders are talking about on Friday are Synergy Pharmaceuticals Inc (NASDAQ:SGYP), PNC Financial Services Group Inc (NYSE:PNC), U.S. Bancorp (NYSE:USB), QUALCOMM, Inc. (NASDAQ:QCOM), and Yahoo! Inc. (NASDAQ:YHOO). Let’s take a look at why each stock is trending and use SEC filings to see what the world’s greatest investors think of the five equities.

At Insider Monkey, we track around 765 hedge funds and institutional investors. Through extensive backtests, we have determined that imitating some of the stocks that these investors are collectively bullish on, can help retail investors generate double digits of alpha per year. The key is to focus on the small-cap picks of these funds, which are usually less followed by the broader market and allow for larger price inefficiencies (see the details here).

Yahoo! Inc. (NASDAQ:YHOO), Yahoo Mail, Sign in, Create Account, Smarphone, Log in

Roman Pyshchyk /

Synergy Retreats on Update 

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares have retreated by 6.7% in morning trading after the biotech issued an update on the ongoing FDA review of the company’s lead product candidate plecanatide for the potential treatment of chronic idiopathic constipation, as well as on the company’s IBS-C clinical development program. According to CEO Gary S. Jacob, Synergy has reached the FDA mid-cycle review milestone and is optimistic about the potential approval of plecanatide for the treatment of CIC by the PDUFA date of January 29, 2017. The company has also decided to continue patient enrollment for two ongoing phase III clinical trials for plecanatide for the potential treatment of IBS-C. Some traders could be selling due to the slower enrollment pace. Synergy remains hopeful that it will file an NDA for plecanatide for the treatment of IBS-C in the first quarter of 2017. Of the 766 active funds that we track, 21 collectively owned $73.66 million worth of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares on March 31, which accounted for 23.50% of the float.

Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Trade (NASDAQ:SGYP) Now!

PNC Reports Mixed Results

PNC Financial Services Group Inc (NYSE:PNC) is slightly in the green this morning after the bank reported earnings of $1.82 per share on revenue of $3.79 billion for the second quarter. The results beat analysts’ bottom-line estimate by $0.07 per share but missed the top-line consensus by $20 million. Net interest income rose by 1% year-over-year while NIM inched lower by 3.0 basis points to 2.7%. PNC’s book value rose to $85.33 per share from $79.64 per share year-over-year. Cliff Asness‘ AQR Capital Management reported holding a stake of more than 4.5 million shares in PNC Financial Services Group Inc (NYSE:PNC) as of the end of March.

Follow Pnc Financial Services Group Inc. (NYSE:PNC)
Trade (NYSE:PNC) Now!

On the next page we’ll find out why US Bancorp, QUALCOMM, and Yahoo are generating buzz this morning.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.